Board of Directors

Joseph Carleone, Ph.D.
Chairman of the Board

Dr. Carleone is Chairman of the Board of AMPAC Fine Chemicals LLC, a leading manufacturer of pharmaceutical active ingredients.  Prior to this position, Dr. Carleone was President, Chief Executive Officer and director of American Pacific Corporation, a leading custom manufacturer of fine and specialty chemicals and propulsion products.  Dr. Carleone has also served or currently serves as an officer and/or a director of several directly or indirectly wholly-owned subsidiaries of American Pacific Corporation.  Dr. Carleone received his bachelor's degree in Mechanical Engineering from Drexel University, Philadelphia, Pennsylvania, in 1968; his master's degree in Applied Mechanics from Drexel University in 1970; and his doctorate degree in Applied Mechanics from Drexel University in 1972.
 

Mark R. Bamforth
Director

Mr. Bamforth has served as a member of the Board of Directors since October 2017. He is the Founder of Arranta Bio, LLC, a new contract development and manufacturing company (“CDMO”) that is being developed to support the microbiome industry.  Previously, Mr. Bamforth served as the President and CEO of Brammer Bio, LLC, in Cambridge, Massachusetts, a cell and gene therapy CDMO with over 600 employees that he founded in 2015 and merged with Florida Biologix, an established, 10-year old CDMO, in March 2016.  Brammer Bio was sold to Thermo Fisher Scientific on April 30, 2019.  Previously, he was the President and Chief Executive Officer of Gallus Biopharmaceuticals, LLC, (“Gallus”), in St. Louis, Missouri, a company that he founded in 2010. Gallus was a process development, clinical and commercial, mammalian cell based bulk biopharmaceuticals CDMO which tripled in size through organic growth and the acquisition of Laureate Biopharma, prior to its acquisition by DPx Holdings B.V., the parent company of Patheon, in 2014. 

Prior to his founding of Arranta Bio, Brammer Bio and Gallus BioPharmaceuticals, Mr. Bamforth spent 22 years with Genzyme Corporation rising to the position of senior vice president of corporate operations and pharmaceuticals.  In this role, he oversaw a multi-technology, global operations team comprised of more than 3,600 individuals at 13 internal sites and a network of 24 contract manufacturing organizations.  This team was charged with supplying over 20 commercial products and multiple clinical products that spanned biologics, cell therapy, gene therapy, pharmaceuticals and biologic devices.  While at Genzyme, Mr. Bamforth served as a member of the CEO's operating committee, helping to guide corporate strategy acquisition, partnering and growth to over $4 billion in sales.

Mr. Bamforth also serves on the boards of MassBio and the Wentworth Institute of Technology, and is a Saltire Foundation founding-trustee. He earned a bachelor of science in chemical engineering from Strathclyde University and an MBA from Henley Management College.

Richard B. Hancock
Director

Mr. Hancock has been a member of the Avid Bioservices Board of Directors since November 2017 and currently serves as the interim President and CEO. He has held a variety of executive positions in biotechnology for over thirty five years, most recently as President and CEO of Althea Technologies where he established its biologics and drug product contract manufacturing services and grew the business from inception to a recognized world leading CDMO with superior profitability and over 200 employees. He managed the acquisition of the company by Ajinomoto with an outstanding return on investment to shareholders. Mr. Hancock began his biotechnology career at Hybritech Inc., (subsequently Eli Lilly and Company) one of the earliest companies developing monoclonal antibodies for diagnostic and therapeutic applications. He held positions of increasing responsibility in Quality Control, Process Development and cGMP Manufacturing. Following Hybritech, he worked at Genetics Institute, (currently a division of Pfizer) in the development and commercialization of several first to market products including recombinant Factor VIII, Factor IX and Bone Morphogenetic Protein. At The Immune Response Corporation, a developer of novel vaccine candidates to treat HIV infection, Multiple Sclerosis, Rheumatoid Arthritis and other autoimmune diseases, he established the company’s Manufacturing, Process Development and Quality organizations and was responsible for production and release of all clinical materials from early stage development and scale-up to commercial readiness. Mr. Hancock currently serves as Executive Chairman of Argonaut Manufacturing Services, a CDMO producing a wide variety of medical devices, molecular diagnostics and parenteral drug products, and is a board member of Tempo Therapeutics. He received a BA in Microbiology from Miami University, Oxford, Ohio.

Catherine Mackey Ph.D.
Director

Catherine J. Mackey, Ph.D., is an experienced leader, director and advisor serving start-up, venture-backed, and public companies. She is the former Sr. Vice President, Pfizer Global R&D, and has over thirty years of research and development and operations experience in the pharmaceutical, biotechnology and agricultural industries.

Dr. Mackey is Chairman of the Board of Directors of Cour Pharmaceutical Development Corporation, a privately-held, clinical-stage company using material science and immunology to cure disease. She is a member of the Board of Directors of GW Pharmaceuticals PLC (NASDAQ: GWPH) a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. She is also a member of the Board of Poseida Therapeutics, Inc., a privately held, clinical stage company developing next generation cell therapies for cancer. Previously she served on the Boards of Evolve Biosystems, Sequenom, Inc. (acquired by Labcorp), Viventia Bio (acquired by Eleven Bio), YM Biosciences (acquired by Gilead), and Althea Technologies (acquired by Ajinomoto). Her current non-profit board service includes Rady Children’s Hospital and Rady Children’s Institute of Genomic Medicine. In addition, she serves as a consultant and advisor to several companies. 

From 2001 through 2010 Dr. Mackey was Sr. Vice President, Pfizer Global Research and Development, and Director, La Jolla Laboratories. She led Pfizer’s La Jolla Labs to become one of Pfizer’s most successful R&D sites. With over 1000 staff located on a one-million square-foot campus, and an annual budget of approximately $300M, Pfizer La Jolla delivered a steady–state pipeline of over two dozen development compounds. This pipeline yielded four key oncology drugs:  sunitinib (Sutent), axitinib (Inlyta), crizotinib (Xalkori), and palbociclib (Ibrance). Dr. Mackey was also a member of Pfizer’s Global Research Leadership Team, which managed the largest R&D budget, organization and portfolio in the industry. In addition, she was a member of Pfizer’s Senior Leadership Team where she acquired broad knowledge and experience across all divisions of the company.

Prior to her leadership role at Pfizer La Jolla, Dr. Mackey led Strategic Alliances at Pfizer’s R&D headquarters, where she gained extensive experience with both corporate and corporate-academic partnerships in the U.S. and global markets. Prior to that role, she led Pfizer’s US R&D efforts in Genomic and Proteomic Sciences, which included biomarker and pharmacogenomics research. Dr. Mackey began her career in agricultural biotechnology, first with Pfizer and then with DEKALB Genetics, Inc. She led the team that won the race to transform corn – a breakthrough that revolutionized the seed industry. Dr. Mackey and her team applied this technology to create several first-in-class commercial products and build a robust patent estate. She also pioneered the application of genomic analysis to commercial breeding. She moved from bench scientist to various roles of increasing responsibility and eventually to corporate Vice President and head of Research and Development for DEKALB Genetics. She was a member of DEKALB’s executive team that sold the company to Monsanto in 1999 at a $3.8 billion market capitalization. Dr. Mackey received her B.S. (‘77) and Ph.D. (‘83) degrees in microbiology from Cornell University.
 

Gregory P. Sargen
Director

Gregory P. Sargen currently serves as Chief Financial Officer and Executive Vice President, Corporate Development and Strategy of Cambrex Corporation (NYSE:CBM) (“Cambrex”), a global manufacturer and provider of services to life sciences companies.  Prior to his current roles, Mr. Sargen served as Executive Vice President, Corporate Development and Strategy, Chief Financial Officer, and Vice President, Finance of Cambrex.  Prior to Cambrex, Mr. Sargen served as Executive Vice President, Chief Financial Officer of Expanets, Inc., Vice President of Finance – Chemicals Manufacturing Division of Fisher Scientific International Inc. (n/k/a Thermo Fisher Scientific Inc.) (NYSE:TMO), and held positions with Merck & Co., Inc. (NYSE:MRK), Heat and Control, Inc. and Deloitte & Touche LLP. Mr. Sargen is a Certified Public Accountant (non-practicing) and holds an MBA in Finance from The Wharton School of the University of Pennsylvania and a B.S. in Accounting from Pennsylvania State University.

Patrick D. Walsh
Director

Mr. Walsh has served as a member of the Board of Directors since October 2017. He currently serves as an Operating Partner at Ampersand Capital, a private-equity healthcare investment firm, and is founder of Diligence Team, LLC, a consulting practice serving clients in the healthcare industry. From 2015-2019 he served as Chief Executive Officer of Avista Pharma Solutions, a high-growth CDMO that was acquired by Cambrex Corp. in January 2019.  Prior to joining Avista Pharma, he was Chief Executive Officer of AAIPharma Services, a private-equity backed CDMO at which he led a successful growth strategy culminating in the company’s sale for more than 4.5 times return on invested capital.  Mr. Walsh also held the positions of President and Chief Operating Officer of Gensia-Sicor, during which time he led the company's commercial growth strategy, culminating in the eventual sale to Teva for $3.4 billion. Prior to Gensia, he spent 10 years in a global pharmaceutical company culminating in leading the U.S. and international business of a leading Japanese pharma company. Mr. Walsh has served on pharmaceutical boards as chairman, non-executive chairman and company director, as well as an executive advisor to private equity and venture capital firms.  Mr. Walsh currently serves as a director of ANI Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical company (NASDAQ:ANIP), since June 2018, and is a member of the Audit and Compensation Committees. He also currently serves on the board of MedPharm, a privately-held dermal CDMO, and serves on the governance and compensation committees.